Data as of Oct 24
| +0.17 / +1.03%|
The 11 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 24.00, with a high estimate of 32.00 and a low estimate of 14.00. The median estimate represents a +43.45% increase from the last price of 16.73.
The current consensus among 11 polled investment analysts is to Buy stock in Keryx Biopharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.